170 related articles for article (PubMed ID: 14762741)
1. Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin).
Zhu X
Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):20-3. PubMed ID: 14762741
[TBL] [Abstract][Full Text] [Related]
2. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
[TBL] [Abstract][Full Text] [Related]
3. Logistics of therapy with the ibritumomab tiuxetan regimen.
Meredith RF
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S35-8. PubMed ID: 16979437
[TBL] [Abstract][Full Text] [Related]
4. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
5. Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Gordon LI
Semin Oncol; 2003 Dec; 30(6 Suppl 17):23-8. PubMed ID: 14710400
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Borghaei H; Schilder RJ
Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):4-9. PubMed ID: 14762738
[TBL] [Abstract][Full Text] [Related]
7. Radiation safety considerations with therapeutic 90Y Zevalin.
Zhu X
Health Phys; 2003 Aug; 85(2 Suppl):S31-5. PubMed ID: 12865747
[TBL] [Abstract][Full Text] [Related]
8. Radiation safety guidelines for radioimmunotherapy with yttrium 90 ibritumomab tiuxetan.
Hendrix C
Clin J Oncol Nurs; 2004 Feb; 8(1):31-4. PubMed ID: 14983760
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
Witzig TE
Semin Oncol; 2003 Dec; 30(6 Suppl 17):11-6. PubMed ID: 14710398
[TBL] [Abstract][Full Text] [Related]
10. Radiation safety with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy.
Hendrix C
Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):14-9. PubMed ID: 15160857
[TBL] [Abstract][Full Text] [Related]
11. Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Spies SM
Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):10-3. PubMed ID: 14762739
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
[TBL] [Abstract][Full Text] [Related]
13. Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.
Micallef IN
Clin Lymphoma; 2004 Oct; 5 Suppl 1():S27-32. PubMed ID: 15498147
[TBL] [Abstract][Full Text] [Related]
14. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician.
Conti PS
Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):2-3. PubMed ID: 14762737
[TBL] [Abstract][Full Text] [Related]
16. Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin).
Gregory SA
Semin Oncol; 2003 Dec; 30(6 Suppl 17):17-22. PubMed ID: 14710399
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
18. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA
Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
[TBL] [Abstract][Full Text] [Related]
19. Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Zimmer AM
Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):14-9. PubMed ID: 14762740
[TBL] [Abstract][Full Text] [Related]
20. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma.
Cheson BD
BioDrugs; 2005; 19(5):309-22. PubMed ID: 16207072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
